FGP
TEVA icon

Freestone Grove Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Freestone Grove Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.5M Buy
604,053
+69,643
+13% +$2.32M 0.13% 203
2026
Q1 		$16.1M Buy
+534,410
New +$17.2M 0.11% 239

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Freestone Grove Partners's TEVA Position: Q2 2026 in Review

Freestone Grove Partners increased its Teva Pharmaceuticals (TEVA) stake by 13% in Q2 2026, buying an estimated $2.32M and bringing the position to 604,053 shares worth $20.5M. The position accounts for 0.13% of the portfolio, ranked #203.

Freestone Grove Partners first reported a position in TEVA in Q1 2026 and has held it in 2 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Freestone Grove Partners held 604,053 shares of Teva Pharmaceuticals worth $20.5M as of Q2 2026.
  • Freestone Grove Partners bought 69,643 Teva Pharmaceuticals shares in Q2 2026, an estimated $2.32M.
  • Teva Pharmaceuticals made up 0.13% of Freestone Grove Partners's portfolio in Q2 2026, its #203 holding.
  • Freestone Grove Partners first reported a position in Teva Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.